Dianeal PD-2

Per 100 mL Dianeal PD-2 peritoneal dialysis soln w/ 1.5% dextrose Dextrose hydrous 1.5 g, NaCl 538 mg, Na lactate 448 mg, Ca chloride 25.7 mg, Mg chloride 5.08 mg. Per 100 mL Dianeal PD-2 peritoneal dialysis soln w/ 2.5% dextrose Dextrose hydrous 2.5 g, NaCl 538 mg, Na lactate 448 mg, Ca chloride 25.7 mg, Mg chloride 5.08 mg. Per 100 mL Dianeal PD-2 peritoneal dialysis soln w/ 4.25% dextrose Dextrose hydrous 4.25 g, NaCl 538 mg, Na lactate 448 mg, Ca chloride 25.7 mg, Mg chloride 5.08 mg

Acute or chronic renal failure when nondialytic medical therapy is judged to be inadequate. Certain fluid & electrolyte disturbances & for patients intoxicated w/ certain poisons & drugs.

IP Intermittent peritoneal dialysis (IPD) Maintenance dialysis of chronic renal failure Sequentially repeat cycle of instillation, dwell & removal of dialysis over period of 8-36 hr as many times/wk as indicated by patient's condition. Chronic renal failure Maintenance: Periodic dialysis (3-5 times wkly) for shorter time period of 8-14 hr/session. Continuous ambulatory peritoneal dialysis (CAPD) Chronic renal failure Maintenance: 4 cycles/day (24 hr). Automated peritoneal dialysis (APD) Chronic renal failure Maintenance: 3-5 cycles at night & up to 2 cycles during day.

Preexisting severe lactic acidosis. Uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase risk of infection. Documented loss of peritoneal function or extensive adhesions that compromise peritoneal function.

IP administration only. Encapsulating peritoneal sclerosis (EPS). Peritonitis. Not to be used to treat patients w/ severe lactic acidosis. Monitor for lactic acidosis in patients w/ conditions known to increase risk of lactic acidosis (eg, acute renal failure, inborn errors of metabolism, treatment w/ drugs eg, metformin & NRTIs) prior to initiation of & during treatment; serum K, Ca & Mg levels in patients treated w/ cardiac glycosides; blood-glucose levels in diabetics during & following dialysis; Ca levels for development of hypocalcemia or worsening of hypercalcemia in patients w/ hypercalcemia. Inspect drained fluid for presence of fibrin or cloudiness. May require replacement of protein, amino acids, water-soluble vit & other drugs during dialysis. Patients w/ abdominal conditions eg, surgical disruption of peritoneal membrane & diaphragm, from congenital anomalies or trauma until healing is complete, abdominal tumors & wall infection, hernias, fecal fistula, colostomy or ileostomy, frequent episodes of diverticulitis, inflammatory or ischemic bowel disease, large polycystic kidneys or other conditions that compromise integrity of abdominal wall, abdominal surface, or intra-abdominal cavity; other conditions including aortic graft placement & severe pulmonary disease. Avoid over- & underhydration. Periodically evaluate serum electrolyte conc (eg, bicarbonate, K, Mg, Ca & phosphate), blood chemistry (eg, parathyroid hormone & lipid parameters) & hematological parameters. May affect ability to drive or use machines. Pregnancy & lactation.

Fungal & bacterial peritonitis, catheter related infection; hypovolemia, hypervolemia, fluid retention, hypokalemia, hyponatremia, dehydration, hypochloremia, hypotension, HTN; dyspnea; sclerosing encapsulating peritonitis, peritonitis, peritoneal cloudy effluent, vomiting, diarrhea, nausea, constipation, abdominal pain, abdominal distension, abdominal discomfort, urticaria, rash, pruritus, myalgia, muscle spasms, musculoskeletal pain; generalized edema, pyrexia, malaise, infusion site pain, catheter-related complication.

May reduce conc of dialyzable drugs.

Intravenous & Other Sterile Solutions

B05DA - Isotonic solutions ; Used in peritoneal dialysis.

Rx